| Autor: |
Sevostyanova, V. V., Antonova, L. V., Silnikov, V. N., Mironov, A. V., Koroleva, L. S., Serpokrilova, I. Yu., Krivkina, E. O., Khanova, M. V., Kudryavtseva, Yu. A., Barbarash, L. S. |
| Předmět: |
|
| Zdroj: |
AIP Conference Proceedings; 2018, Vol. 2051 Issue 1, p020274-1-020274-5, 5p, 1 Diagram, 2 Charts |
| Abstrakt: |
Immobilization of arginylglycylaspartic acid (RGD)-containing peptides at the luminal surface is a promising approach to increase biocompatibility of tissue-engineered vascular grafts, yet there is still unknown whether structure of RGD-containing peptides and length of their linker affect implantation outcome. Here we fabricated 1.5 mm diameter electrospun poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/poly(ε-caprolactone) vascular grafts and further immobilized RGDK, AhRGD, and c[RGDFK] peptides using either hexamethylenediamine or 4,7,10-trioxa-1,13-tridecanediamine as a short and long linker, respectively. In vivo biocompatibility of the grafts was assessed employing rat infrarenal aorta interposition model. Rats were sacrificed 1 and 3 months postoperation with the following histological examination of the grafts by hematoxylin and eosin, van Gieson, and alizarin red S staining. We found that RGDK- and c[RGDFK]-treated grafts demonstrated better performance compared to AhRGD-modified grafts. Moreover, immobilization of RGDcontaining peptides using a long linker 4,7,10-trioxa-1,13-tridecanediamine led to the higher biocompatibility of the grafts in comparison with a short linker hexamethylenediamine. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
